Status:
COMPLETED
An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will provide treatment with erlotinib to participants with advanced NSCLC who have received at least one course of standard chemotherapy or radiation therapy, or who are not medically suita...
Eligibility Criteria
Inclusion
- Adults greater than or equal to (≥) 18 years of age
- Histologically or cytologically documented inoperable, locally advanced, metastatic, or recurrent NSCLC
- Previous treatment with no more than 2 prior chemotherapy regimens
Exclusion
- Previous systemic anti-cancer therapy with human epidermal growth factor receptor 1 (HER1)/epidermal growth factor receptor (EGFR) inhibitors
- Inability to take oral medication
- Any other malignancies within 5 years
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
6586 Patients enrolled
Trial Details
Trial ID
NCT00949910
Start Date
November 1 2004
End Date
April 1 2009
Last Update
October 5 2016
Active Locations (543)
Enter a location and click search to find clinical trials sorted by distance.
1
Tirana, Albania, 1000
2
Buenos Aires, Argentina, 1272
3
Buenos Aires, Argentina, 1427
4
Buenos Aires, Argentina, 1437